Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AR 08

Drug Profile

AR 08

Alternative Names: AR-08

Latest Information Update: 22 Mar 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arbor Pharmaceuticals
  • Class
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Psychiatric disorders

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder
  • Suspended Vasomotor symptoms

Most Recent Events

  • 11 Feb 2015 Arbor Pharmaceuticals terminates a phase II trial in Vasomotor symptoms in USA (NCT02049164)
  • 01 Feb 2015 Arbor Pharmaceuticals completes a phase II trial in Attention-deficit hyperactivity disorder (In children, adolescents) in USA (NCT01876719)
  • 11 Jun 2014 Arbor Pharmaceuticals suspends enrolment in a phase II trial for Vasomotor symptoms in USA (NCT02049164)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top